Long-term safety of pirtobrutinib in people with chronic lymphocytic leukemia
Studies long-term safety of pirtobrutinib in adults with previously treated leukemia or lymphoma.
Plain-language title generated from the registry record
Registry title: A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Key facts
- Where
- Santander and Seville, SpainSee the 2 sites
- Phase
- Phase 4
Where in Spain
- Hospital Universitario Marqués de ValdecillaSantander, SpainNot yet recruiting
- Hospital Universitario Virgen del RocioSeville, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07218341
- Record updated
- 4 November 2026
- Original description
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.Read full original descriptionShow less
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Inclusion: Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020.
Exclusion: This is not applicable to this study.